The Department of Health and Human Services (HHS) announced on Tuesday that a total of 22 mRNA vaccine development contracts worth approximately $500 million have been terminated. These investments were part of the Biomedical Advanced Research and Development Authority (BARDA), which focuses on scientific research for developing vaccines, drugs, and tools to combat national health threats.
HHS Secretary Robert F. Kennedy Jr. stated that the decision to cancel the 22 mRNA vaccine development investments was based on data showing that these vaccines are ineffective in protecting against upper respiratory infections like COVID and flu. The funds from these terminated contracts will be redirected towards safer and more reliable vaccine platforms that can remain effective even as viruses mutate.
Kennedy highlighted the drawbacks of mRNA vaccines, pointing out their limited efficacy against upper respiratory viruses and their inability to defend against mutations. He emphasized that mRNA vaccines can inadvertently encourage the development of new virus variants, potentially prolonging pandemics.
Despite canceling the mRNA contracts under BARDA, ongoing mRNA research at the National Institutes of Health (NIH) will not be affected. The focus will now shift towards developing safer and more comprehensive vaccine strategies, such as whole virus vaccines and novel platforms that are more resilient to virus mutations.
Kennedy reassured the public of his support for safe and effective vaccines, emphasizing the importance of moving beyond the limitations of mRNA technology for respiratory viruses. The goal is to invest in better solutions to protect public health.
